Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis AG with three other
companies in this sector in the United States:
Roche Holding Aktiengesellschaft
sales of $51.16 billion
of which 77%
of which 55%
was Operating Segment-Global Innovative Phar), and
of which 35%
was Pharmaceuticals & Biological Products).
Novartis AG reported sales of $49.39 billion
December of 2016.
decrease of 1.9%
versus 2015, when the company's sales were $50.36 billion.
Contributing to the drop in overall sales was the 40.8% decline
in Alcon, from $9.81 billion to $5.81 billion.
However, these declines were partially offset by the increase in sales of
Innovative Medicines (up 7.0% to $32.56 billion)
Sandoz (up 10.8% to $10.14 billion)